This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lin, H. Articles by Morin, P. J. Search for Related Content PubMed PubMed Citation Articles by Lin, H. Articles by Morin, P. J.

Frequent Silencing of the GPC3 Gene in Ovarian Cancer Cell Lines

Laboratory of Biological Chemistry [H. L., P. J. M.], and Laboratory of Genetics [R. H., D. S.], Gerontology Research Center, National Institute on Aging, Baltimore, Maryland 21224, and Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287 [P. J. M.]

GPC3 encodes a glypican integral membrane protein and is mutated in the Simpson-Golabi-Behmel syndrome. Simpson-Golabi-Behmel syndrome, an X-linked condition, is characterized by pre- and postnatal overgrowth as well as by various other abnormalities, including increased risk of embryonal tumors. The GPC3 gene is located at Xq26, a region frequently deleted in advanced ovarian cancers. To determine whether GPC3 is a tumor suppressor in ovarian neoplasia, we studied its expression and mutational status in 13 ovarian cancer cell lines. No mutations were found in GPC3, but its expression was lost in four (31%) of the cell lines analyzed. In all of the cases where GPC3 expression was lost, the GPC3 promoter was hypermethylated, as demonstrated by Southern analysis. Expression of GPC3 was restored by treatment of the cells with the demethylating agent 5-aza-2'-deoxycytidine. A colony-forming assay confirmed that ectopic GPC3 expression inhibited the growth of ovarian cancer cell lines. Our results show that GPC3, a gene involved in the control of organ growth, is frequently inactivated in a subset of ovarian cancers and suggest that it may function as a tumor suppressor in the ovary.

This article has been cited by other articles:

				T. Ishiguro, M. Sugimoto, Y. Kinoshita, Y. Miyazaki, K. Nakano, H. Tsunoda, I. Sugo, I. Ohizumi, H. Aburatani, T. Hamakubo, et al. Anti-Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer Cancer Res., December 1, 2008; 68(23): 9832 - 9838. [Abstract] [Full Text] [PDF]

				W. Cheng, C.-J. Tseng, T. T.C. Lin, I. Cheng, H.-W. Pan, H.-C. Hsu, and Y.-M. Lee Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway Carcinogenesis, July 1, 2008; 29(7): 1319 - 1326. [Abstract] [Full Text] [PDF]

				D. Qiao, X. Yang, K. Meyer, and A. Friedl Glypican-1 Regulates Anaphase Promoting Complex/Cyclosome Substrates and Cell Cycle Progression in Endothelial Cells Mol. Biol. Cell, July 1, 2008; 19(7): 2789 - 2801. [Abstract] [Full Text] [PDF]

				M. I. Capurro, Y.-Y. Xiang, C. Lobe, and J. Filmus Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt Signaling Cancer Res., July 15, 2005; 65(14): 6245 - 6254. [Abstract] [Full Text] [PDF]

				T. Nakatsura, H. Komori, T. Kubo, Y. Yoshitake, S. Senju, T. Katagiri, Y. Furukawa, M. Ogawa, Y. Nakamura, and Y. Nishimura Mouse Homologue of a Novel Human Oncofetal Antigen, Glypican-3, Evokes T-Cell-Mediated Tumor Rejection without Autoimmune Reactions in Mice Clin. Cancer Res., December 15, 2004; 10(24): 8630 - 8640. [Abstract] [Full Text] [PDF]

				T. Nakatsura, T. Kageshita, S. Ito, K. Wakamatsu, M. Monji, Y. Ikuta, S. Senju, T. Ono, and Y. Nishimura Identification of Glypican-3 as a Novel Tumor Marker for Melanoma Clin. Cancer Res., October 1, 2004; 10(19): 6612 - 6621. [Abstract] [Full Text] [PDF]

				I. I. de Caceres, C. Battagli, M. Esteller, J. G. Herman, E. Dulaimi, M. I. Edelson, C. Bergman, H. Ehya, B. L. Eisenberg, and P. Cairns Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients Cancer Res., September 15, 2004; 64(18): 6476 - 6481. [Abstract] [Full Text] [PDF]

				R. J. de Leeuw, J. J. Davies, A. Rosenwald, G. Bebb, R. D. Gascoyne, M. J.S. Dyer, L. M. Staudt, J. A. Martinez-Climent, and W. L. Lam Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes Hum. Mol. Genet., September 1, 2004; 13(17): 1827 - 1837. [Abstract] [Full Text] [PDF]

				E. J. Davies, F. H. Blackhall, J. H. Shanks, G. David, A. T. McGown, R. Swindell, R. J. Slade, P. Martin-Hirsch, J. T. Gallagher, and G. C. Jayson Distribution and Clinical Significance of Heparan Sulfate Proteoglycans in Ovarian Cancer Clin. Cancer Res., August 1, 2004; 10(15): 5178 - 5186. [Abstract] [Full Text] [PDF]

				Y. Hippo, K. Watanabe, A. Watanabe, Y. Midorikawa, S. Yamamoto, S. Ihara, S. Tokita, H. Iwanari, Y. Ito, K. Nakano, et al. Identification of Soluble NH2-Terminal Fragment of Glypican-3 as a Serological Marker for Early-Stage Hepatocellular Carcinoma Cancer Res., April 1, 2004; 64(7): 2418 - 2423. [Abstract] [Full Text] [PDF]

				J. Sugimura, R. S. Foster, O. W. Cummings, E. J. Kort, M. Takahashi, T. T. Lavery, K. A. Furge, L. H. Einhorn, and B. T. Teh Gene Expression Profiling of Early- and Late-Relapse Nonseminomatous Germ Cell Tumor and Primitive Neuroectodermal Tumor of the Testis Clin. Cancer Res., April 1, 2004; 10(7): 2368 - 2378. [Abstract] [Full Text] [PDF]

				H. Kim, G.-L. Xu, A. C. Borczuk, S. Busch, J. Filmus, M. Capurro, J. S. Brody, J. Lange, J. M. D'Armiento, P. B. Rothman, et al. The Heparan Sulfate Proteoglycan GPC3 Is a Potential Lung Tumor Suppressor Am. J. Respir. Cell Mol. Biol., December 1, 2003; 29(6): 694 - 701. [Abstract] [Full Text] [PDF]

				B. De Cat, S.-Y. Muyldermans, C. Coomans, G. Degeest, B. Vanderschueren, J. Creemers, F. Biemar, B. Peers, and G. David Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements J. Cell Biol., November 10, 2003; 163(3): 625 - 635. [Abstract] [Full Text] [PDF]

				A. Scherpereel, T. Gentina, B. Grigoriu, S. Senechal, A. Janin, A. Tsicopoulos, F. Plenat, D. Bechard, A.-B. Tonnel, and P. Lassalle Overexpression of Endocan Induces Tumor Formation Cancer Res., September 15, 2003; 63(18): 6084 - 6089. [Abstract] [Full Text] [PDF]

				M. A. Aldred, M. E. Ginn-Pease, C. D. Morrison, A. P. Popkie, O. Gimm, C. Hoang-Vu, U. Krause, H. Dralle, S. M. Jhiang, C. Plass, et al. Caveolin-1 and Caveolin-2,Together with Three Bone Morphogenetic Protein-related Genes, May Encode Novel Tumor Suppressors Down-Regulated in Sporadic Follicular Thyroid Carcinogenesis Cancer Res., June 1, 2003; 63(11): 2864 - 2871. [Abstract] [Full Text] [PDF]

				P. S. Yan, C.-M. Chen, H. Shi, F. Rahmatpanah, S. H. Wei, C. W. Caldwell, and T. H.-M. Huang Dissecting Complex Epigenetic Alterations in Breast Cancer Using CpG Island Microarrays Cancer Res., December 1, 2001; 61(23): 8375 - 8380. [Abstract] [Full Text] [PDF]

				Z-W Zhu, H Friess, L Wang, M Abou-Shady, A Zimmermann, A D Lander, M Korc, J Kleeff, and M W Buchler Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders Gut, April 1, 2001; 48(4): 558 - 564. [Abstract] [Full Text] [PDF]

				R. M. Davison, M. Fox, and G.S. Conway Mapping of the POF1 locus and identification of putative genes for premature ovarian failure Mol. Hum. Reprod., April 1, 2000; 6(4): 314 - 318. [Abstract] [Full Text] [PDF]